We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bad scrip

30 September 2004 By Robert Cyran

The US drugs giant has stopped selling its blockbuster arthritis treatment because the pill increases the risk of heart attack and stroke. If investors seem to be panicking, it is because the withdrawal compounds other problems: a dry pipeline and generic competition.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)